FDA accepts NDA for pixantrone, a treatment for non-Hodgkin's lymphoma (NHL)

Cell Therapeutics announced that the FDA has accepted for filing the New Drug Application (NDA) submitted for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). Pixantrone is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from currently marketed anthracyclines and other related chemotherapy agents. Pixantrone also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

For more information call (800) 215-CELL or visit www.celltherapeutics.com.